Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
Results support combination strategy for influenza vaccines
Original title: “Osivax reports phase 2b data for OVX836”
GSK’s vaccine—which targets two primary flu antigens—elicited higher immune responses in both younger and older adults in a mid-stage study. The Phase 3 launch, planned for September, follows the FDA's recent approval for Moderna’s mRNA flu vaccine.
Original title: “GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality”
Information on flu, COVID, RSV and other respiratory infections and relation to asthma
Original title: “Respiratory Infections and Asthma”
Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.
Original title: “FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax”
The FDA in February slapped Moderna’s vaccine with a refusal-to-file letter—though the agency backtracked a few days later and accepted a revised submission for review. An advisory committee in June unanimously backed mFLUVISA’s approval.
Original title: “Moderna’s flu shot crosses FDA finish line, bouncing back from regulatory roadblock”
severe pneumonia and acute respiratory distress syndrome caused by avian influenza a h10n3 in a young female a case report
Original title: “Severe pneumonia and acute respiratory distress syndrome caused by avian influenza A (H10N3) in a young female: a case report.”
After getting slapped with a surprise refuse-to-file letter signed by former CBER Director Vinay Prasad, Moderna’s flu vaccine application will now go before the FDA’s Vaccine advisory committee.
Original title: “Moderna’s once-rebuffed mRNA flu shot to face scrutiny from FDA adcomm”
By partnering with a UN-backed body, Roche has enabled companies to make the medicine for supply in 129 countries.
Original title: “Roche licensing pact clears generic drugmakers to manufacture antiviral flu drug”
This report describes survey results from backyard flock owners’ attitudes towards avian influenza.
Original title: “Knowledge, Attitudes, and Practices Regarding Avian Influenza Among Owners of Backyard Flocks — United States, July–December 2025”
post marketing active surveillance of adverse events following quadrivalent subunit influenza vaccine in healthy participants aged 3 years in china
Original title: “Post-Marketing Active Surveillance of Adverse Events Following Quadrivalent Subunit Influenza Vaccine in Healthy Participants Aged ≥ 3 Years in China.”
genetic and biological characterization of h9n2 avian influenza viruses isolated from swine in china
Original title: “Genetic and biological characterization of H9N2 avian influenza viruses isolated from swine in China.”
This news announcement was updated on 7 May 2026 to include additional recommendations for strains for seasonal egg-derived and live-attenuated influenza vaccinesEMA has issued…
Original title: “EU recommendations for 2026/2027 seasonal flu vaccine composition”
This report describes interim estimates of 2025-26 flu vaccine effectiveness in California during October 2025-January 2026.
Original title: “Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — California, October 2025–January 2026”
This report describes interim estimates of 2025-26 seasonal flu vaccine effectiveness.
Original title: “Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — United States, September 2025–February 2026”
global evolutionary landscape of h11 avian influenza and initial isolates identified in xinjiang china
Original title: “Global evolutionary landscape of H11 avian influenza and initial isolates identified in Xinjiang, China.”
In issuing a positive recommendation, the EMA has diverged from the FDA, which has set higher approval standards for Moderna’s vaccine in the U.S.
Original title: “Moderna’s combination flu, COVID shot wins over European drug regulators”
Flu is a contagious respiratory illness that infect the nose, throat, and sometimes the lungs.
Original title: “About Influenza”
The disagreement between Moderna and the FDA has reached a resolution just eight days after the biotech received a Refusal-to-File letter in response to its application for mRNA-1010. Moderna will now seek approval of the vaccine based on age.
Original title: “FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision”
Moderna said after a "Type A" meeting, the agency agreed to move forward and review its application for the mRNA-based shot.
Original title: “FDA reverses course on Moderna’s flu vaccine”
The FDA outright refuses to review Moderna’s mRNA-based flu vaccine as CBER director Vinay Prasad’s conduct is scrutinized; Disc Medicine receives an unexpected rejection, which Prasad may also have had a hand in; Compass Pathways posts new late-stage data on its psilocybin-based depression drug; CDC is once again leaderless.
Original title: “Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders”